Does Rallies show Form 4 insider transactions for PRLD?

Yes. Rallies tracks PRLD insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is PRLD research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PRLD. It does not provide personalized investment advice.

PRLD (Prelude Therapeutics Incorporated) Stock Analysis - Insider Trades

Prelude Therapeutics Incorporated (PRLD) is a publicly traded Healthcare sector company. As of May 21, 2026, PRLD trades at $4.51 with a market cap of $345.66M and a P/E ratio of -4.37. PRLD moved +5.50% today. Year to date, PRLD is +84.43%; over the trailing twelve months it is +358.25%. Its 52-week range spans $0.61 to $5.54. Analyst consensus is strong buy with an average price target of $7.67. Rallies surfaces PRLD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading PRLD stock inside the company?

Recent PRLD insider activity includes Bonita David P bought 1.69M, Bonita David P bought 1.13M, ORBIMED ADVISORS LLC bought 1.69M, ORBIMED ADVISORS LLC bought 1.13M, and Combs Andrew bought 100.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

PRLD Key Metrics

Key financial metrics for PRLD
Metric	Value
Price	$4.51
Market Cap	$345.66M
P/E Ratio	-4.37
EPS	$-1.00
Dividend Yield	0.00%
52-Week High	$5.54
52-Week Low	$0.61
Volume	27
Avg Volume	0
Revenue (TTM)	$16.72M
Net Income	$-77.80M
Gross Margin	0.00%

Recent PRLD Insider Trades

Bonita David P bought 1.69M (~$7.50M) on Apr 21, 2026.
Bonita David P bought 1.13M (~$5.00M) on Apr 21, 2026.
ORBIMED ADVISORS LLC bought 1.69M (~$7.50M) on Apr 21, 2026.
ORBIMED ADVISORS LLC bought 1.13M (~$5.00M) on Apr 21, 2026.
Combs Andrew bought 100.00K (~$69.25K) on Mar 25, 2025.

Latest PRLD News

Prelude Therapeutics Advances PRT12396 Trial and Secures Cash Runway to Q2 2028 — May 12, 2026
Prelude Therapeutics Prices $90M Equity Offering at $4.44 per Share — Apr 20, 2026
Prelude’s PRT13722 Achieves Complete Tumor Regressions and Improved Safety, IND in Mid-2026 — Apr 20, 2026
Prelude Therapeutics Appoints CMO With 30 Years’ Experience for 2026 Trials — Apr 15, 2026
Prelude Therapeutics Gets FDA IND Clearance for JAK2 Inhibitor, Reports $106M Cash Runway — Mar 10, 2026

PRLD Analyst Consensus

3 analysts cover PRLD: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.67.

Common questions about PRLD

Who is trading PRLD stock inside the company?: Recent PRLD insider activity includes Bonita David P bought 1.69M, Bonita David P bought 1.13M, ORBIMED ADVISORS LLC bought 1.69M, ORBIMED ADVISORS LLC bought 1.13M, and Combs Andrew bought 100.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for PRLD?: Yes. Rallies tracks PRLD insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is PRLD research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PRLD. It does not provide personalized investment advice.